AstraZeneca set to showcase the latest in respiratory science at the 2019 American Thoracic Society (ATS) International Conference
We aim to transform the treatment of respiratory disease with our growing portfolio of inhaled and biologic medicines, along with scientific research targeting the underlying causes of the diseases. We look forward to joining clinicians, researchers and scientists at the 2019 American Thoracic Society (ATS) International Conference to share the latest in respiratory science advancements.
The story of life with severe asthma
Affecting as many as an estimated 34 million people worldwide, severe asthma is a distinct form of asthma that can seriously impact the lives of those living with it. Award-winning documentary filmmaker, Michelle Coomber, shines a light on the realities of living with severe asthma and the opportunities to improve care for patients around the world. We stand with the asthma community to call for increased recognition of the burden of severe asthma. Watch, share, stand with us.
Aiming for disease modification in Respiratory
Our research ambition is to modify, and ultimately cure, respiratory disease. We believe we can do so by addressing the underlying biological drivers of the disease, through our expanded toolbox of drug modalities that go beyond the more traditional small molecules and monoclonal antibodies.
We believe this could allow us to target any novel biology we uncover, and to access targets in the body that were previously seen as hard-to-reach.
Our strategic research involves understanding biologic drivers through four mechanistic and complimentary approaches in chronic lung disease. We investigate what might be the best delivery routes for our drug modalities whether that be systemic or inhaled treatments.
Supporting changes in respiratory clinical care
PRECISION: Fundamentally improving the lives of people living with severe asthma
PRECISION represents AstraZeneca’s broader commitment to ensuring that severe asthma patients can realise better outcomes and experiences through improving the design and delivery of severe asthma care. By 2021, PRECISION will improve the patient journey for people living with severe asthma. PRECISION will deliver new or updated national quality standards for severe asthma.
Spotlight On: Addressing airway inflammation in asthma
Asthma, an inflammatory disease, affects the health and day-to-day lives of as many as 339 million people worldwide. With recurring flare-ups of inflammation, experts are calling for a potential new approach to asthma care. We believe the management of asthma should be directed towards preventing and resolving the inflammatory process to help reduce the risk of preventable asthma attacks.
Pushing the boundaries to deliver innovative solutions
_-_Scaled_(71%)_-_2019-01-04_12.03.06.png/_jcr_content/renditions/cq5dam.web.320.Screen_Shot_2018-09-13_at_14.05.47.png_(PNG_Image,_1692_×_1288_pixels)_-_Scaled_(71%)_-_2019-01-04_12.03.06.png){kind=tracking}
Maria Belvisi
Senior Vice President and Head of Research and Early Development, RIA, R&D BioPharmaceuticals
Tom Keith-Roach
Senior Vice President, Respiratory, Therapeutic Area
Rene van der Merwe
Vice President, Clinical Respiratory
Join Us. Be at the Forefront of Respiratory Health.
Within Respiratory at AstraZeneca, we’re driven by innovation and our commitment to make a real-life difference in patients’ lives. That difference starts with you. As one of Science Magazine’s 2018 Top Employer, we need people like you who share our passion for science and determination to meet patients’ needs around the world.
Veeva ID: Z4-16875
Date of next review: May 2020